{"anticipatedPostingDate":"2027-06","denomUnitsSelected":"Participants","description":"Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 73 months","title":"Progression-free Survival on Subsequent Line of Therapy (PFS2)","type":"SECONDARY"}